Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



Vanderbilt Takes Investigational New Drug From Bench To Bedside


 
P. Jeffrey Conn, PhD

Patients with serious brain disorders such as Alzheimer's disease and schizophrenia could benefit from an investigational new drug (IND) that has received notification from the FDA that testing in humans may proceed after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

"This is the first instance I am aware of where an academic drug discovery group moved a molecule for treatment of chronic brain disorders all the way from early discovery to human trials without there being, at some point along the way, a pharmaceutical partner," said P. Jeffrey Conn, PhD, director, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). "And that really is crossing what people refer to all of the time as the 'Valley of Death,' where good research discoveries have a hard time moving into the real testing phase."

For Alzheimer's disease, the IND targets major pathologies of the disease and offers highly selective activation of a key receptor unlike the current standard of care, cholinesterase inhibitors. Vanderbilt researchers said the molecule might be broadly effective across a number of cognitive and neuropsychiatric disorders. In schizophrenia, current treatments address the positive symptoms of the disease, including hallucinations and delusions, but not the negative symptoms and cognitive disturbances of schizophrenia. "People who treat schizophrenia patients commonly agree that the negative symptoms and cognitive disturbances are the major factors that decrease the ability for these patients to integrate in society," Conn said. "And we have no treatments for those so our hope is that this molecule will be effective."

VCNDD Co-Director Craig W. Lindsley, PhD, director of Medicinal Chemistry and the William K. Warren, Jr. Chair in Medicine, said phase I testing will assess drug safety and tolerability in young healthy volunteers, a process that could take a year. If successful, the phase II and III studies would include patients with either Alzheimer's disease or schizophrenia and could take three-five years to complete.

 
Share:

Related Articles:


Recent Articles

Tax Reform & Healthcare

Medicare cuts and repeal of the individual mandate are two areas of tax reform directly impacting healthcare.

Read More

Senate HELP Committee Hearing on Gene Editing Technology

On Nov. 14, the Senate health committee held a hearing on the gene editing method CRISPR to learn more about the technology from expert witnesses, which included Dr. Matthew Porteus, associate professor of Pediatrics at Stanford University; Katrine Bosley, CEO and president of Editas Medicine; and Dr. Jeffrey Kahn, director of the Johns Hopkins Berman Institute of Bioethics at Johns Hopkins School of Public Health.

Read More

Nashville Health Care Council Hosts Panel Discussion on Pharma/Provider Collaborations in Health Care

On Nov. 13, the Nashville Health Care Council hosted a panel discussion on collaborations between the pharmaceutical and healthcare provider sectors and how those collaborations can drive change in healthcare.

Read More

Tennessee Health Care Hall of Fame Class of 2017

Six healthcare luminaries were recently inducted into the Tennessee Health Care Hall of Fame.

Read More

NMGMA 10 Minute Takeaway

Nashville Medical News recently had the opportunity to chat with new NMGMA president Joy Testa.

Read More

Tennessee Joins Medical Licensing Compact

A new Tennessee law will make it easier for area physicians to practice across state lines beginning in 2019 as part of the Interstate Medical Licensure Compact.

Read More

A Plan to Address COPD

COPD is the third leading cause of death in America, yet it lags behind many other conditions in terms of research dollars and coordinated federal response ... but that seems to be changing.

Read More

Surgical Innovations

Two new procedures recently made their debut in Middle Tennessee offering new treatment options for coronary bifurcation lesions and lumbar fusion.

Read More

Don't fear the FBAR

If you are a taxpayer with offshore financial accounts, you could be in trouble with the IRS and not even know it.

Read More

HoneyCo Homes: Using Smart Technology to Help Seniors Age in Place

A Nashville startup is using technology to help seniors age in place while providing peace of mind to loved ones and actionable data to caregivers.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: